title: Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
abstract: BACKGROUND
  There are few studies analyzing the behavior of ustekinumab in the complex management of psoriasis within diary clinical practice setting.
  
  
  OBJECTIVE
  To assess the utility of ustekinumab in a psoriasis unit.
  
  
  METHODS
  Analysis of the prospective data gathered during the follow-up of 30 consecutive psoriasis patients treated with ustekinumab at a single referral centre. Three effectiveness endpoints were defined 12 weeks, 28 and "long-term treatment". The main outcome measure was improvement from baseline PASI at week 28 and at a point of adjustment of prolonged treatment signed as "long-term treatment".
  
  
  RESULTS
  Overall 82.1% and 42.8% patients achieved respectively PASI75 and PASI90 response rates at week 28. Long-term treatment maintained efficacy outcomes 81.5% and 40.7% PASI75 and PASI90, respectively were observed. At week 28, patients naïve to TNFα- blockers agents and patients with a baseline PASI >10 had better PASI75 and PASI90 response rates than previously treated patients.
  
  
  CONCLUSIONS
  In clinical practice, the efficacy and patient adherence to ustekinumab are excellent and even better to the data obtained in clinical trials. Clinical indicators of psoriasis severity: previous treatments with tumor necrosis factor α blockers agents and active treatment beside small increases in PASI determine a delayed maximal response.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Molina-Leyva
authors.forename: Husein
authors.initials: H
authors.lastname: Husein-Elahmed
authors.forename: Ramon
authors.initials: R
authors.lastname: Naranjo-Sintes
authors.forename: Jose Carlos
authors.initials: JC
authors.lastname: Ruiz-Carrascosa
mesh_terms: D004334:Drug Administration Schedule; D006801:Humans; D008499:Medical Records; D010349:Patient Compliance; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000069549:Ustekinumab